GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Shin Nippon Biomedical Laboratories Ltd (FRA:YB3) » Definitions » 5-Year EBITDA Growth Rate

Shin Nippon Biomedical Laboratories (FRA:YB3) 5-Year EBITDA Growth Rate : 24.40% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Shin Nippon Biomedical Laboratories 5-Year EBITDA Growth Rate?

Shin Nippon Biomedical Laboratories's EBITDA per Share for the three months ended in Dec. 2023 was €0.18.

During the past 12 months, Shin Nippon Biomedical Laboratories's average EBITDA Per Share Growth Rate was -5.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 17.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 24.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 23.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shin Nippon Biomedical Laboratories was 153.90% per year. The lowest was -36.80% per year. And the median was 16.50% per year.


Competitive Comparison of Shin Nippon Biomedical Laboratories's 5-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shin Nippon Biomedical Laboratories's 5-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shin Nippon Biomedical Laboratories's 5-Year EBITDA Growth Rate falls into.



Shin Nippon Biomedical Laboratories 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Shin Nippon Biomedical Laboratories  (FRA:YB3) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Shin Nippon Biomedical Laboratories 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shin Nippon Biomedical Laboratories's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Shin Nippon Biomedical Laboratories (FRA:YB3) Business Description

Traded in Other Exchanges
Address
8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.

Shin Nippon Biomedical Laboratories (FRA:YB3) Headlines

No Headlines